Transgene begins trials of head and neck cancer vaccine

Virus-based immunotherapy biotech Transgene is to begin clinical trials of its head and neck cancer drug candidate TG4050 after gaining regulatory clearance from the UK regulator.<

GSK hires former Genentech expert for AI unit

Scotland backs Pfizer’s Ibrance for breast cancer

FDA reviews Sanofi's multiple myeloma drug isatuximab

The FDA has begun its review of Sanofi’s multiple myeloma drug isatuximab, as the French pharma prepares for a tussle with Johnson & Johnson’s blockbuster Darzalex.

Array, Pierre Fabre bowel cancer therapy ‘could replace chem...